Skip to content

NAD+ IV Drip

NAD+ infusion for energy and cellular health. IV Therapy.

Intelligence Profile

Research Papers

Research Papers and Clinical Trials

The research landscape for NAD+ IV therapy is currently limited, with most available evidence focusing on related NAD+ compounds rather than direct intravenous NAD+ administration.

Key Studies

A 2026 retrospective pilot study published in Frontiers in Aging directly compared intravenous NAD+ infusions with nicotinamide riboside (NR) supplementation in a real-world clinical setting, focusing on tolerability outcomes. However, specific study details including sample size and methodology are not available from the current evidence.

A systematic review published in Ageing Research Reviews (2026) examined NAD+ supplementation broadly for anti-aging and wellness applications using PRISMA guidelines. This review synthesized both preclinical and clinical evidence, though it appears to cover various forms of NAD+ supplementation rather than focusing specifically on IV administration.

Related Research

Several studies have examined related NAD+ precursors and metabolites. A 2021 study in the International Journal of Molecular Sciences investigated nicotinamide mononucleotide's effects on glucose tolerance and insulin clearance in the context of free fatty acid-induced metabolic changes, though this focused on a different NAD+ precursor rather than direct NAD+ infusion.

Clinical Trials

Current clinical trial activity includes a Phase 1 study (NCT06558253) examining "Coenzyme I for Injection" for hematopoietic recovery after stem cell transplantation, which is currently recruiting participants. Another trial (NCT07328100) is planned but not yet recruiting to evaluate Coenzyme I's effects on vascular aging, though neither study design details nor sample sizes are available.

Evidence Limitations

The available evidence base for NAD+ IV therapy specifically remains thin. Most research focuses on oral NAD+ precursors or related compounds rather than direct intravenous NAD+ administration. The clinical trials identified do not provide sufficient detail to assess study methodology or expected enrollment numbers.

This information is for educational purposes only and should not replace consultation with a healthcare provider for medical advice.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.